N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 1 ClinicalTrials.gov

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Sponsor: Pliant Therapeutics, Inc. • ClinicalTrials.gov ID: NCT06270706

Registry updated: 2026-10-02
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study treatment regimen) in adult participants with advanced or metastatic solid tumors for which pembrolizumab is indicated but have documented disease progression (refractory \[primary resistance\]) or relapsed \[secondary resistance\]) after at least 3 months from the start of treatment with pembrolizumab. The study will consist of 2 main parts: * Part 1: Consecutive dose-escalation cohorts using a Bayesian optimal interval (BOIN) dose escalation design with accelerated titration * Part 2: Dose-expansion cohorts using Simon's 2-stage design

Interventions

  • PLN-101095 (Drug)
    PLN-101095 250 mg BID
  • PLN-101095 (Drug)
    PLN-101095 500 mg BID
  • PLN-101095 (Drug)
    PLN-101095 1000 mg BID
  • PLN-101095 (Drug)
    PLN-101095 1000 mg TID
  • PLN-101095 (Drug)
    PLN-101095 2000 mg BID
  • PLN-101095 (Drug)
    PLN-101095
  • Pembrolizumab (Drug)
    Pembrolizumab (KEYTRUDA) 200 mg IV Q3W

Eligibility criteria

Inclusion Criteria: 1. Has histologically or cytologically confirmed advanced or metastatic solid tumor 2. Have received ≥12 weeks of continuous anti-PD-1 or anti-PD-L1 treatment administered as monotherapy or in combination with other anticancer therapies 3. Have demonstrated documented prior clinical benefit, defined as CR or PR at any time during treatment, or SD lasting ≥6 months (Part 2 only) 4. Must have subsequently developed radiographic disease progression while receiving anti-PD-1 or anti-PD-L1 treatment or within ≤12 weeks after the last dose of such treatment 5. At least 1 measurable lesion, as defined by RECIST v1.1 6. Estimated survival of ≥3 months 7. Have adequate bone marrow and organ function. 8. A female participant is eligible to participate if she is not pregnant, not breastfeeding Exclusion Criteria: 1. Any immune-related medical conditions that would put participants at greater risk when receiving pembrolizumab 2. Has a known additional malignancy that is progressing or has required active treatment within the past 2 years 3. Has received prior radiotherapy within 2 weeks for palliative bone-directed therapy and 4 weeks for all other radiotherapy 4. Has undergone major surgery within 4 weeks prior to the first dose of study treatment or has not adequately recovered from surgery or related complications 5. Has a diagnosis of immunodeficiency or use of systemic steroids \>10 mg/day 6. Has an active autoimmune disease that has required systemic treatment in the past 2 years 7. Has known active CNS metastases (brain and/or leptomeningeal metastases) 8. Has significant cardiac disease 9. Has an active infection requiring systemic therapy (including uncontrolled HIV, Hepatitis B and C) 10. Has received a live or live-attenuated vaccine within 30 days or a non-live vaccine within 7 days prior to the first dose of PLN-101095

Conditions

Advanced or Metastatic Solid Tumor

Locations

  • Yale University — New Haven, Connecticut, United States
  • Winship Cancer Institute of Emory University — Atlanta, Georgia, United States
  • South Texas Accelerated Research Therapeutics (START) — Grand Rapids, Michigan, United States
  • Washington University Medicine — St Louis, Missouri, United States
  • START New Jersey — East Brunswick, New Jersey, United States
  • START New York Long Island LLC — Lake Success, New York, United States
  • Carolina Cancer Research Center — Wilson, North Carolina, United States
  • Avera Medical Group — Sioux Falls, South Dakota, United States
  • Tennessee Oncology — Nashville, Tennessee, United States
  • NEXT Austin — Austin, Texas, United States
  • START Center for Clinical Research — Fort Worth, Texas, United States
  • University of Texas MD Anderson Cancer Center — Houston, Texas, United States
  • NEXT Houston — Houston, Texas, United States
  • START Mountain Region — West Valley City, Utah, United States
  • Inova Schar Cancer Institute — Fairfax, Virginia, United States
  • NEXT Virginia — Fairfax, Virginia, United States
  • Hospital Universitari Quirónsalud (NEXT Barcelona) — Barcelona, Barcelona, Spain
  • START Barcelona - Hospital HM Nou Delfos — Barcelona, Barcelona, Spain
  • START Center for Cancer Research - La Rioja — Logroño, La Rioja, Spain
  • START Madrid - Hospital Universitario Fundación Jiménez Díaz — Madrid, Madrid, Spain
  • START Madrid - Centro Integral Oncológico Clara Campal — Madrid, Madrid, Spain
  • University Hospital Quironsalud Madrid (NEXT Madrid) — Madrid, Pozuelo de Alarcón, Spain
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record